CD274 and neoplasm: To further evaluate the impact of CMscore on tumor’s response to immunotherapy, we first investigated a large cohort of patients with metastatic urothelial cancer (mUC) treated with atezolizumab, an anti-PD-L1 agent (the IMvigor210 study) [55].